Stanford Dropout Says Blood Startup Won't Be Another Theranos

Re:Stanford Dropout Says Blood Startup Won't Be Another Ther... by Balgair on Monday August 28, 2017 @03:46PM (#15119485)

What are false-positive and false negative rates for Circulating Tumor Cells with your tech?

Do you control for age and other bio-factors and how?

[ Parent | on HN ]

Re:Stanford Dropout Says Blood Startup Won't Be Another Ther... by ttandon on Monday August 28, 2017 @05:13PM (#15120120)

CTCs are a very early application in our tech and one that we're excited to continue working on. We have some strong sample share relationships with Stanford and sensitivity/stage/specificity testing is in its early stages right now. Will publish on the data page when more information

[ Parent | on HN ]

Re:Stanford Dropout Says Blood Startup Won't Be Another Ther... by Balgair on Tuesday August 29, 2017 @02:37PM (#15126569)

Look at CU-Anschutz as well, CCTSI is very active in CTCs.

[ Parent | on HN ]